19-Nor Pyrazolyl Steroid Modulates GABAA Receptors for Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for major depressive disorder (MDD) and postpartum depression (PPD) with elevated anxiety often fail to provide adequate relief, as they do not effectively target the underlying neurochemical imbalances that contribute to both depressive symptoms and anxiety.
Innovation Solution
Administration of Compound (1), a neuroactive steroid that acts as a positive allosteric modulator of GABAA receptors, in a therapeutically effective amount, either as a free compound or its pharmaceutically acceptable salt, for a duration of about 14 days or 2 weeks, at doses ranging from 20 mg to 55 mg, via various routes including oral, parenteral, and transdermal, to modulate brain excitability and reduce anxiety and depressive symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for MDD and PPD are used, then they are administered to patients, but they fail to provide adequate relief from depressive symptoms and anxiety due to inability to effectively target neurochemical imbalances
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of neuroactive steroids to create Compound (1) with optimized properties. Specifically, the compound features a 19-norpregnane backbone with a 3α-hydroxy-3β-methyl-5β-tetrasubstituted structure, where substituents at positions 2 and 21 (including the pyrazolyl group at position 21) are carefully selected to enhance GABAA receptor binding affinity and modulatory activity. This structural parameter optimization enables the compound to effectively target neurochemical imbalances involving GABA, glutamate, and serotonin systems, thereby resolving the contradiction between treatment reliability and neurochemical targeting capability
Solution Approach 2:
Compound (1) acts as an intermediary substance that mediates the interaction between the administered drug and multiple neurochemical systems. The compound serves as a positive allosteric modulator of GABAA receptors while simultaneously influencing glutamate and serotonin transmission. This intermediary role allows a single compound to address multiple neurochemical imbalances that contribute to depression and anxiety, thereby improving treatment efficacy without requiring multiple separate medications
2Object-affected harmful factors
If GABAA receptor modulation is enhanced to reduce anxiety, then brain excitability is controlled, but the complexity of targeting multiple neurochemical systems increases
Solution Approach 1:
Compound (1) exhibits multi-functionality by simultaneously modulating three distinct neurochemical systems: GABAergic transmission through positive allosteric modulation of GABAA receptors, glutamatergic transmission through effects on NMDA and AMPA receptors, and serotonergic transmission through 5-HT1A receptor modulation. This universal action across multiple neurochemical systems allows a single compound to address the complex interplay between anxiety, depression, and brain excitability, reducing the need for multiple specialized medications and simplifying treatment protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound (1) significantly reduces Hamilton Rating Scale scores for anxiety and depression, achieving substantial symptom relief within 15 days, with sustained improvements in both depressive and anxiety symptoms, as demonstrated by clinical trial data, indicating its efficacy in treating MDD and PPD with elevated anxiety.
Implementation Method 1
GABA interacts with its recognition site on the GRC (GABA receptor complex) to facilitate the flow of chloride ions down an electrochemical gradient of the GRC into the cell
Implementation Method 2
Compound (1), a neuroactive steroid that acts as a positive allosteric modulator of GABAA receptors
Data Source
AI summary
The present disclosure relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof. The disclosure also relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof.